ALX-0141

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameALX-0141
Drug Alias NameALX-0141EDP-406
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis, PostmenopausalBone Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesAblynx Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAblynx NvEddingpharm (China) Co Ltd
Active IndicationsN/A
Inactive IndicationsOsteoporosis, PostmenopausalBone Diseases

Other Information

ATC CodeN/A
Related LinksN/A